• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

Record of Telephone Conversation-Cervarix, August 9, 2007

Record of Telephone Conversation

STN Number: 125259/0
Manufacturer: GlaxoSmithKline Biologicals
Product: Human Papillomavirus Vaccine, ASO4 Adjuvant-Adsorbed

To: File
From: Helen S. Gemignani, Regulatory Project Manager
Subject: MPL Safety Analysis Plan Statistical Discussion
Telecon Date: August 9, 2007 Telecon Time: 11:30 am – 12:00 pm
Telecon Initiated by: GSK
Contact Phone: 610 787-3726 Mr. Whitman
 Signature:


Summary of Telecon

As a follow up to this morning's telecon (9-10 AM), this 11:30 am telecon discussed the details of the statistical analysis plan and how to analyze the combined data from all studies for products that have MPL. Dr. Lee clarified the issues of a weighted, fixed effect, true meta-analysis. GSK's statisticians were in agreement. GSK and CBER were in agreement and this issue of analysis has been resolved.

GSK indicated that the CBER recommendation for a true meta-analysis will not impact on the timelines that they proposed for submission of data from their clinical studies for products that include MPL.

End of Teleconference

Action Items

  • GSK will perform a true meta-analysis and submit to CBER by August 27, 2007.   

FDA Participants

  • Gopa Raychaudhuri
  • Nancy Miller
  • Martha Lee
  • Amelia Dale Horne
  • Helen Gemignani

GSK Participants

  • Amy Scott
  • Vince Ahonkai
  • Matt Whitman
  • Gary Dubin
  • Brigitte Cheuvart
  • Fabian Tibaldi
  • Marie-Pierre David